<?xml version='1.0' encoding='utf-8'?>
<document id="18311908"><sentence text="Characterization of type II ligands in CYP2C9 and CYP3A4." /><sentence text="Type II cytochrome P450 (CYP) ligands cause inhibition by direct coordination to the heme iron atom"><entity charOffset="90-94" id="DDI-PubMed.18311908.s2.e0" text="iron" /></sentence><sentence text=" This interaction usually leads to high inhibitory potential, which can cause drug-drug interaction" /><sentence text=" The approach to design compounds with diminished CYP inhibition is different depending on whether the compound binds (type II ligand) or not (type I ligand) to the iron atom of the heme group"><entity charOffset="165-169" id="DDI-PubMed.18311908.s4.e0" text="iron" /></sentence><sentence text=" In this study, the structural characteristics of nitrogen-containing compounds, which bind to the iron atom in two CYP isoforms (CYP2C9 and CYP3A4), were investigated"><entity charOffset="50-58" id="DDI-PubMed.18311908.s5.e0" text="nitrogen" /><entity charOffset="99-103" id="DDI-PubMed.18311908.s5.e1" text="iron" /><pair ddi="false" e1="DDI-PubMed.18311908.s5.e0" e2="DDI-PubMed.18311908.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18311908.s5.e0" e2="DDI-PubMed.18311908.s5.e1" /></sentence><sentence text=" The in vitro assays applied were fluorescence inhibition assay, difference spectra measurements, and K s determination" /><sentence text=" Computational modeling as an alternative method to difference spectra measurements to distinguish between type I and type II ligands was also explored" /><sentence text=" Since two CYP isoforms were used, information about the isoform specificity of type II ligands was also analyzed" /><sentence text=" The in silico method developed in this study applied together with the information gained from the experimental measurements may result in better decisions during the drug discovery process" /><sentence text="" /></document>